<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204184">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000796</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 238</org_study_id>
    <secondary_id>CPCRA 026</secondary_id>
    <secondary_id>11215</secondary_id>
    <nct_id>NCT00000796</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.</brief_title>
  <official_title>A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the demographic, behavioral, clinical, and geographic risk factors associated
      with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB). To evaluate the
      clinical and microbiological responses and overall survival of MDRTB patients who are
      treated with levofloxacin-containing multiple-drug regimens chosen from a hierarchical list.
      Per 9/28/94 amendment, to assess whether persistent or recurrent positive sputum cultures of
      patients who show failure or relapse are due to the same strain or reinfection with a new
      strain.

      Among TB patients, there has been an increase in progressive disease due to the emergence of
      antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify
      patients at high risk for MDRTB increases the hazard for both treatment failure and
      development of resistance to additional therapeutic agents. Efforts to improve survival in
      patients with MDRTB will depend on improved methods of assessing the risk of acquisition of
      MDRTB and identifying drug susceptibility patterns in a timely fashion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among TB patients, there has been an increase in progressive disease due to the emergence of
      antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify
      patients at high risk for MDRTB increases the hazard for both treatment failure and
      development of resistance to additional therapeutic agents. Efforts to improve survival in
      patients with MDRTB will depend on improved methods of assessing the risk of acquisition of
      MDRTB and identifying drug susceptibility patterns in a timely fashion.

      Patients are asked a series of questions to determine epidemiologic factors that may be
      predictive of MDRTB. Patients who are determined to be at low risk for MDRTB will be
      referred to another TB treatment protocol (ACTG 222), if appropriate. Patients suspected of
      having primary or acquired MDRTB or those with confirmed MDRTB will be offered a regimen of
      anti-TB therapy from a hierarchically ordered list of drugs, based on the patient's
      resistance status (suspect primary MDRTB, suspect acquired MDRTB, or confirmed MDRTB). The
      hierarchical list is as follows: isoniazid, rifampin, ethambutol, streptomycin,
      levofloxacin, ethionamide, cycloserine, capreomycin, aminosalicylic acid, and clofazimine.
      Treatment will be administered daily for at least 6 months, then on an intermittent schedule
      at the clinician's discretion. Patients with confirmed MDRTB (defined as known resistance to
      at least isoniazid and rifampin within 6 months prior to study entry) will receive a minimum
      of 18 months of treatment following sputum culture conversion. Follow-up is performed every
      4 weeks for 8 weeks, and then every 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">October 1998</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Primary Purpose: Treatment</study_design>
  <enrollment>525</enrollment>
  <condition>HIV Infections</condition>
  <condition>Tuberculosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycloserine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethionamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capreomycin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminosalicylic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Streptomycin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amikacin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofazimine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  Working diagnosis of HIV infection.

          -  Working diagnosis of pulmonary TB.

        Per 08/02/94 amendment, patients with confirmed MDRTB or known susceptibilities for the
        current episode at baseline are not eligible for the epidemiologic study only.

        FOR TREATMENT PILOT:

          -  Positive sputum AFB smear (or a positive sputum culture for TB within 6 months prior
             to study entry).

          -  Assessment of suspect primary, suspect acquired, AND/OR confirmed MDRTB.

          -  Life expectancy of at least 2 weeks.

          -  Age &gt;= 18 years for suspect MDRTB. Age &gt;= 13 years for confirmed MDRTB.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Known hypersensitivity or resistance to quinolones.

          -  Other disorders or conditions for which the study drugs are contraindicated.

        Prior Medication:

        Excluded:

          -  More than 6 weeks total therapy within 3 months prior to study entry using three or
             more drugs effective against the isolates. (Per 08/02/94 amendment, patients from
             protocol ACTG 222/CPCRA 019 who have MDRTB are eligible for rollover to this study
             regardless of treatment duration on ACTG 222/CPCRA 019.)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Telzak E</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Benson C</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Chirgwin K</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Sepkowitz K</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Cook County Hosp</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hosp</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Lebanon Hosp Ctr</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Municipal Hosp Ctr/Jacobi Med Ctr</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Health Care Ctr / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jack Weiler Hosp / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10465</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Drug Treatment Ctr / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Family Health Ctr / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Med Ctr / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Central Bronx Hosp / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samaritan Village Inc / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interfaith Med Ctr</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>112032098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY / Health Sciences Ctr at Brooklyn</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>112032098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hosp / New York Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Directors Network of Region II</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>100323784</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem AIDS Treatment Group / Harlem Hosp Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Clare's Hosp and Health Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&amp;Search=On&amp;int_id=109</url>
    <description>Click here for more information about Rifampin</description>
  </link>
  <link>
    <url>http://aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&amp;Search=On&amp;int_id=123</url>
    <description>Click here for more information about Isoniazid</description>
  </link>
  <reference>
    <citation>Telzak EE, Chirgwin KD, Nelson ET, Matts JP, Sepkowitz KA, Benson CA, Perlman DC, El-Sadr WM. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health. Int J Tuberc Lung Dis. 1999 Apr;3(4):337-43.</citation>
    <PMID>10206505</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <lastchanged_date>March 30, 2012</lastchanged_date>
  <firstreceived_date>November 2, 1999</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Isoniazid</keyword>
  <keyword>Tuberculosis, Pulmonary</keyword>
  <keyword>Pyrazinamide</keyword>
  <keyword>Pyridoxine</keyword>
  <keyword>Ofloxacin</keyword>
  <keyword>Rifampin</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Ethambutol</keyword>
  <keyword>Clofazimine</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Amikacin</keyword>
  <keyword>Drug Resistance, Microbial</keyword>
  <keyword>Cycloserine</keyword>
  <keyword>Capreomycin Sulfate</keyword>
  <keyword>Ethionamide</keyword>
  <keyword>Aminosalicylic Acids</keyword>
  <keyword>Streptomycin</keyword>
  <keyword>p-Aminosalicylic Acid</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Aminosalicylic Acid</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Capreomycin</mesh_term>
    <mesh_term>Clofazimine</mesh_term>
    <mesh_term>Cycloserine</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Ethionamide</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Streptomycin</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
